RNS Number : 6267Q
Genedrive PLC
28 October 2021

genedrive plc
("genedrive" or the "Company")

**Notice of Results**

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it will release its financial results for the year ended 30 June 2021 on Tuesday 9 November 2021.

genedrive will be hosting a live online presentation on Thursday, 11 November at 14:00, delivered by David Budd, CEO.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via:
https://www.investormeetcompany.com/genedrive-plc/register-investor

Investors who already follow genedrive plc on the Investor Meet Company platform will automatically be invited.

For further details please contact:

| | |
|---|---|
| **genedrive plc**<br>David Budd: CEO / Matthew Fowler: CFO | +44 (0)161 989 0245 |
| **Peel Hunt LLP (Nominated Adviser and Joint Broker)**<br>James Steel | +44 (0)20 7418 8900 |
| **finnCap (Joint Broker)**<br>Geoff Nash / Kate Bannatyne / Alice Lane | +44 (0)20 7220 0500 |
| **Walbrook PR Ltd (Media & Investor Relations)**<br>Paul McManus / Anna Dunphy | +44 (0)20 7933 8780 or genedrive@walbrookpr.com<br>+44 (0)7980 541 893 / +44 (0)7876 741 001 |

**About genedrive plc** (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, Antibiotic Induced Hearing Loss and certain military biological targets. The Company released a high throughput SARS-CoV-2 assay in 2020 and has a point of care version of the SARS-Cov-2 test due on market during 2021.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORMPBITMTJTBPB